WEBSITE


TMUNITY
UNCANCER THE WORLD™
RELENTLESSLY ENGINEERING THE BEST T CELL MEDICINES FOR SOLID TUMOR PATIENTS
WHY TMUNITY?


TMUNITY
UNCANCER THE WORLD™
RELENTLESSLY ENGINEERING THE BEST T CELL MEDICINES FOR SOLID TUMOR PATIENTS
WHY TMUNITY?

WEBSITE


TMUNITY
UN
PRECE
DENTED
We know from experience that innovation doesn't follow the beaten path, and that fresh ways of thinking can be the only way to shift existing paradigms. Our modular engineering approach is uniquely positioned to revolutionize T cell therapies.
PEOPLE AND PARTNERS
SCIENCE AND TECHNOLOGY
PRODUCTS AND PIPELINE


TMUNITY
UN
WAVERING
We have dedicated our life's work to the fight against cancer, inspired by patients to give our best and never give up. The journey to a cure has been long and uncertain, but our belief in the power of T cells never falters.
OUR STORY
OUR PEOPLE
SCIENCE AND TECHNOLOGY


TMUNITY
UN
RELENTING
Our serial innovation approach to CAR T development means that each new generation builds on previous discoveries, resulting in iterative advancements in safety and efficacy.
SCIENCE AND TECHNOLOGY
PRODUCTS AND PIPELINE

WEBSITE


TMUNITY
UN
WAVERING
The fight against cancer is our life's work. We're united by a shared purpose and fueled by our determination to maximize the therapeutic potential of T cells for solid tumors.


TMUNITY
UN
RELENTING
Our serial innovation approach to CAR T development means that each new generation builds on previous discoveries, resulting in iterative advancements in safety and efficacy.


TMUNITY
UN
PRECE
DENTED
We know from experience that innovation doesn't follow the beaten path, and that fresh ways of thinking can be the only way to shift existing paradigms. Our modular engineering approach is uniquely positioned to revolutionize T cell therapies.

WEBSITE


TMUNITY
CUSTOMIZABLE CAR T VECTORS
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque
EXPLORE
ENGINEERED T CELLS
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium
EXPLORE


ANTIGEN RECOGNITION
Tmunity's proprietary binders recognize a range of targets on solid tumors. Multiple binders can be deployed within a cell to deal with variable solid tumor antigen expression.
PSMA, PSCA Prostate
TnMUC-1 Pancreatic, non-small cell lung, triple-negative breast, ovarian
MESO Lung, ovarian, pancreatic, mesothelioma
FRα Ovarian, lung, breast, cervix, endometrial, kidney, bladder
GPC2 Neuroblastoma, small cell lung, neuroendocrine tumors
EGFR Glioblastoma
IL13Rα2 Glioblastoma, pancreatic
FAP Prostate, lung, pancreatic, breast, ovarian, oral, gastric, colon, glioblastoma, esophageal, mesothelioma
1 2 CO-STIMULATORY DOMAINS 3 ARMORS, ENHANCERS, SWITCHES
ANTIGEN RECOGNITION


CO-STIMULATORY DOMAINS
Modules dial up or down the "engine" of T cell activation, with the potential to create CAR Ts with the optimal profile for efficacy, safety, and persistence needed to eradicate a variety of solid tumors.
CD2
4-1BB
ICOS
CD27
1 ANTIGEN RECOGNITION 2 3 ARMORS, ENHANCERS, SWITCHES
CO-STIMULATORY DOMAINS

WEBSITE

TMUNITY

SERIAL INNOVATION FEEDS OUR PIPELINE

Iterative learnings from our clinical programs inform the creation of our next generation products.

TMUNITY

SCIENTIFIC FOUNDERS

CARL H. JUNE, MD
SCIENTIFIC FOUNDER

VIEW BIO

VIEW MANAGEMENT

TMUNITY

OUR CURRENT PIPELINE

A diversified portfolio of validated and novel targets in cross clinical development addressing the needs of a range of solid tumors.

① **PSMA**
TmPSMA-01: PSMA 41bbz + dnTGF-βRII

TUMOR TYPE:
Prostate Cancer

PRECLINCAL | PHASE 1 | PHASE 2/3

EXPLORE

② **TnMUC1 Positive**
TmTnMUC1-01: TnMUC1 CD2z

TUMOR TYPE:
Lung, Pancreatic, Triple-Negative Breast, and Ovarian Cancer

PRECLINCAL | PHASE 1 | PHASE 2/3

EXPLORE

③ **Mesothelin Positive**
TmMSLN-01: MSLN 41bbz

TUMOR TYPE:



MICROENVIRONMENT MODULATION

To counter the immunosuppressive tumor environment, T cells can be engineered to enhance or block cytokines and express switch receptors to modulate checkpoint signaling.

dnTGFβ-R2:
Improves CAR T proliferation and expansion potential by neutralizing TGFb signaling.

TGFβ/IL-12R switch receptor:
Improves CAR T proliferation and expansion potential by switching the inhibitory effects of TGF-β signaling into a stimulatory IL-12R signal.

PD1/CD28 switch receptor:
Improve CAR T antitumor activity and reduce tumor-induced inhibition by leveraging the overexpression PD-L1 on tumor cells and switching its inhibitory effects into a stimulatory CD28 signal

PROTOTYPING

View Prototype ›